Search research articles
Contact Us
Filters
Showing results (661-670 of 715) with videos related to
Page
of 72
Sort By:
Blood Advances
|
June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib
Francesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Frontiers in Neurology
|
February 6, 2026
The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity
Lotta Völker, Leonie Müller-Jensen, Sophia Carl, et al.
Blood
|
June 3, 2026
Type I interferon-activated NK cells control polycythemia vera in vivo
Johanna Lossa, Tina M Schnöder, Zora Ronge, et al.
Genome Biology
|
January 21, 2011
Comparative and functional genomics provide insights into the pathogenicity of dermatophytic fungi
Anke Burmester, Ekaterina Shelest, Gernot Glöckner, et al.
Blood Advances
|
May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
David M Ross, Florian H Heidel, Andrew C Perkins, et al.
Nature Cancer
|
October 31, 2023
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia
Claudia Bruedigam, Amy H Porter, Axia Song, et al.
Leukemia Research
|
October 16, 2018
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Hematological Oncology
|
February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients
Giulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hematological Oncology
|
April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Blood Cancer Journal
|
June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis
Philipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Page
of 72
Search research articles
Search
Showing results (661-670 of 715) with videos related to
Sort By:
Page
of 72
Blood Advances
|
June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib
Francesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Frontiers in Neurology
|
February 6, 2026
The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity
Lotta Völker, Leonie Müller-Jensen, Sophia Carl, et al.
Blood
|
June 3, 2026
Type I interferon-activated NK cells control polycythemia vera in vivo
Johanna Lossa, Tina M Schnöder, Zora Ronge, et al.
Genome Biology
|
January 21, 2011
Comparative and functional genomics provide insights into the pathogenicity of dermatophytic fungi
Anke Burmester, Ekaterina Shelest, Gernot Glöckner, et al.
Blood Advances
|
May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
David M Ross, Florian H Heidel, Andrew C Perkins, et al.
Nature Cancer
|
October 31, 2023
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia
Claudia Bruedigam, Amy H Porter, Axia Song, et al.
Leukemia Research
|
October 16, 2018
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Hematological Oncology
|
February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients
Giulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hematological Oncology
|
April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Blood Cancer Journal
|
June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis
Philipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Page
of 72